➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,669,096


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,669,096
Title:Stable pharmaceutical formulations of methylnaltrexone
Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
Inventor(s): Sanghvi; Suketu P. (Kendall Park, NJ), Boyd; Thomas A. (Grandview, NY)
Assignee: Progenics Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:14/039,866
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,669,096
Patent Claims: 1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.

2. The pharmaceutical preparation of claim 1, wherein less than 1% methylnaltrexone degradation products form following 12 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

3. The pharmaceutical preparation of claim 1, wherein less than 1% methylnaltrexone degradation products form following 24 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

4. The pharmaceutical preparation of claim 3, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.01 to 100 mg/ml.

5. The pharmaceutical preparation of claim 4, wherein the concentration of methylnaltrexone or salt thereof ranges from 1.0 to 50.0 mg/ml.

6. The pharmaceutical preparation of claim 5, wherein the concentration of methylnaltrexone or salt thereof is about 20 mg/ml.

7. The pharmaceutical preparation of claim 5, wherein the chelating agent consists of dipotassium edetate, disodium edetate, edetate calcium disodium, sodium edetate, trisodium edetate, potassium edetate, or a combination thereof.

8. The pharmaceutical preparation of claim 7, wherein the chelating agent consists of edetate calcium disodium.

9. The pharmaceutical preparation of claim 8, wherein the chelating agent concentration ranges from about 0.001 to about 100 mg/ml.

10. The pharmaceutical preparation of claim 9, wherein the chelating agent concentration ranges from about 0.1 to about 25.0 mg/ml.

11. The pharmaceutical preparation of claim 10, wherein the chelating agent concentration is about 0.1 to about 2.5 mg/ml.

12. The pharmaceutical preparation of claim 5, further comprising an isotonicity agent.

13. The pharmaceutical preparation of claim 7, further comprising an isotonicity agent.

14. The pharmaceutical preparation of claim 8, further comprising an isotonicity agent.

15. The pharmaceutical preparation of claim 5, wherein the preparation comprises a buffering agent.

16. The pharmaceutical preparation of claim 7, wherein the preparation comprises a buffering agent.

17. The pharmaceutical preparation of claim 8, wherein the preparation comprises a buffering agent.

18. The pharmaceutical preparation of claim 7, further comprising a preservative and an isotonicity agent.

19. The pharmaceutical preparation of claim 18, wherein the preparation comprises a buffering agent.

20. The pharmaceutical preparation of claim 1, wherein the preparation comprises a solution of methylnaltrexone bromide.

21. The pharmaceutical preparation of claim 1, wherein less than 2% methylnaltrexone degradation products form following 12 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

22. The pharmaceutical preparation of claim 1, wherein the preparation is processed under at least one sterilization technique.

23. The pharmaceutical preparation of claim 1, wherein the solution has a pH from about 3.0 to about 3.5.

24. The pharmaceutical preparation of claim 1, wherein the solution has a pH of about 3.5.

25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.

26. The stable pharmaceutical preparation of claim 25, wherein the solution has a pH ranging from about 3 to about 3.5.

27. The stable pharmaceutical preparation of claim 26, wherein the solution has a pH of about 3.5.

28. The pharmaceutical preparation of claim 25, wherein the pharmaceutical preparation is stable to storage for 3 months at about room temperature.

29. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 6 months at about room temperature.

30. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 12 months at about room temperature.

31. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 24 months at about room temperature.

32. The pharmaceutical preparation of claim 26, wherein the concentration of methylnaltrexone or salt thereof is about 20 mg/ml.

33. The pharmaceutical preparation of claim 32, wherein the concentration of EDTA or derivative thereof ranges from about 0.3 to about 0.5 mg/ml.

34. The pharmaceutical preparation of claim 25, wherein about 1% or less methylnaltrexone degradation products form following 3 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

35. The pharmaceutical preparation of claim 27, wherein about 1% or less methylnaltrexone degradation products form following 6 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

36. The pharmaceutical preparation of claim 27, wherein about 1% or less methylnaltrexone degradation products form following 12 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

37. The pharmaceutical preparation of claim 27, wherein about 1% or less methylnaltrexone degradation products form following 24 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

38. The stable pharmaceutical preparation of claim 25, wherein the methylnaltrexone or salt thereof is methylnaltrexone bromide and is at a concentration of about 20 mg/mL, wherein the EDTA or a derivative thereof is at a concentration of about 0.3 to about 0.5 mg/ml, wherein the solution has a pH of about 3.5.

39. The stable pharmaceutical preparation of claim 38, wherein about 1% or less methylnaltrexone degradation products form following 3 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Harvard Business School
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.